Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group.

J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23.

PMID:
17452677
2.

A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.

Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):809-16. Epub 2007 Mar 23.

PMID:
17363191
3.

Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.

Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, Deniaud-Alexandre E, Ruszniewski P, Touboul E, Labianca R, de Gramont A, Louvet C.

J Clin Oncol. 2007 Jan 20;25(3):326-31.

PMID:
17235048
4.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H.

JAMA. 2007 Jan 17;297(3):267-77.

PMID:
17227978
5.

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.

Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.

J Clin Oncol. 2006 Aug 20;24(24):3946-52.

PMID:
16921047
6.

Palliative biliary stents for obstructing pancreatic carcinoma.

Moss AC, Morris E, Mac Mathuna P.

Cochrane Database Syst Rev. 2006 Apr 19;(2):CD004200. Review.

PMID:
16625598
7.

Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.

J Clin Oncol. 2006 Jan 20;24(3):379-85. Epub 2005 Dec 12.

PMID:
16344320
8.

Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.

Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA.

Br J Cancer. 2005 Jul 25;93(2):195-9.

9.

A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.

Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW; European Study Group for Pancreatic Cancer.

N Engl J Med. 2004 Mar 18;350(12):1200-10. Erratum in: N Engl J Med. 2004 Aug 12;351(7):726.

10.

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J.

J Clin Oncol. 2003 Sep 15;21(18):3402-8. Epub 2003 Jul 28.

PMID:
12885837

Supplemental Content

Support Center